Mimicking the BH3 domain to kill cancer cells

Oncogene

Volumn 27, Issue , 2008, Pages S149-S157

  Chonghaile, T Ni ^a   Letai, A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Bcl 2; BH3 mimetic; Cancer; Drug resistance and ABT 737

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; ANTINEOPLASTIC AGENT; BH3 PROTEIN; BH3 PROTEIN MIMETIC; CITRININ; GOSSYPOL; GOSSYPOL DERIVATIVE; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PEPTIDOMIMETIC AGENT; PROTEIN BCL 2; TETROCARCIN A; TW 37; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; FOLLICULAR LYMPHOMA; GLIOMA; HUMAN; LEUKEMIA; LUNG SMALL CELL CANCER; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MITOCHONDRION; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; DIMERIZATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MITOCHONDRIA; MULTIGENE FAMILY; NEOPLASM PROTEINS; NEOPLASMS; NITROPHENOLS; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES; THIONUCLEOTIDES;

EID: 68149112387     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.52     Document Type: Article

References (93)

1. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. (2002). Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 9: 423-432.
2. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L et al. (1998). Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
3. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D et al. (2004). Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 11: 389-395.
4. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
5. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ et al. (1995). Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11: 1921-1928.
6. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
7. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P et al. (2007). A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26: 2374-2380.
8. Chen S, Dai Y, Harada H, Dent P, Grant S. (2007). Mcl-1 downregulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782-791.
9. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711.
10. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI et al. (1995). Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374: 733-736.
11. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS. (1995). A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 11: 1693-1698.
12. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949.
13. Cleary ML, Sklar J. (1985). Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82: 7439-7443.
14. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK et al. (1994). Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049-3055.
15. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T et al. (2001). Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3: 173-182.
16. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. (2007). Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117: 112-121.
17. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. (2008). BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111: 2300-2309.
18. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. (2007). BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12: 171-185.
19. Eskes R, Desagher S, Antonsson B, Martinou JC. (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935.
20. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
21. Gibson L, Holmgreen SP, Huang DC, Bernard O, Copeland NG, Jenkins NA et al. (1996). bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13: 665-675.
22. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
23. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. (1993). bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82: 1820-1828.
24. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
25. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ. (1997). Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective antiapoptotic Bcl-2 family members. Proc Natl Acad Sci USA 94: 12401-12406.
26. Huang S, Sinicrope FA. (2008). BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 68: 2944-2951.
27. Inohara N, Ding L, Chen S, Nunez G. (1997). Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 16: 1686-1694.
28. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. (2003). Puma is an essential mediator of p53-dependent and-independent apoptotic pathways. Cancer Cell 4: 321-328.
29. Johnstone RW, Ruefli AA, Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164.
30. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al. (2006). Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-1358.
31. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. (2003). Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46: 4259-4264.
32. Klasa RJ, Gillum AM, Klem RE, Frankel SR. (2002). Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12: 193-213.
33. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. (2006). Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388.
34. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z et al. (2008). Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68: 3413-3420.
35. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. (2000). Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7: 1166-1173.
36. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90: 3516-3520.
37. Kutuk O, Letai A. (2008). Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994.
38. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525-535.
39. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R et al. (2002). Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111: 331-342.
40. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM et al. (2007). Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14: 1711-1713.
41. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192.
42. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. (2004). Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6: 241-249.
43. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. (2007). 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972-3979.
44. Martinou JC, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M et al. (1994). Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 13: 1017-1030.
45. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, de Witte T et al. (1998). Hematopoietic malignancies demonstrate lossof-function mutations of BAX. Blood 91: 2991-2997.
46. Meijerink JP, Smetsers TF, Sloetjes AW, Linders EH, Mensink EJ. (1995). Bax mutations in cell lines derived from hematological malignancies. Leukemia 9: 1828-1832.
47. Miyashita T, Reed JC. (1993). Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157.
48. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G et al. (2007). Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13: 2226-2235.
49. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS et al. (1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381: 335-341.
50. Nakano K, Vousden KH. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694.
51. Nakashima T, Miura M, Hara M. (2000). Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60: 1229-1235.
52. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517.
53. O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23: 7697-7702.
54. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S et al. (1998). Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-395.
55. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
56. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
57. Oltvai ZN, Milliman CL, Korsmeyer SJ. (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
58. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. (1999). The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3: 287-296.
59. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE et al. (2001). Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293: 1829-1832.
60. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC et al. (1997). Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969.
61. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC et al. (1998). Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92: 234-240.
62. Reed JC. (2003). Apoptosis-targeted therapies for cancer. Cancer Cell 3: 17-22.
63. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M et al. (1997). Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983-986.
64. Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, Takaoka A et al. (2003). Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 17: 2233-2238.
65. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D et al. (2008). Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14: 3268-3277.
66. Strasser A, Harris AW, Bath ML, Cory S. (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
67. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al. (2008). Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656.
68. Takahashi M, Saito H, Atsukawa K, Ebinuma H, Okuyama T, Ishii H. (2003). Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells. Hepatol Res 25: 192-201.
69. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. (2007a). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438.
70. Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y et al. (2007b). The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13: 621-629.
71. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
72. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. (1985). The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390-1393.
73. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J et al. (2001). Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3: 183-191.
74. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
75. Vaux DL, Cory S, Adams JM. (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442.
76. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC et al. (2006). A novel BH3 mimetic reveals a mitogenactivated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348-11359.
77. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. (2003). p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038.
78. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P et al. (2008). A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15: 820-830.
79. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. (2000). Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97: 7124-7129.
80. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. (1996). BID: a novel BH3 domain-only death agonist. Genes Dev 10: 2859-2869.
81. Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S et al. (2008). TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 123: 958-966.
82. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M et al. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14: 2060-2071.
83. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730.
84. Weiss LM, Warnke RA, Sklar J, Cleary ML. (1987). Molecular analysis of the t(14; 18) chromosomal translocation in malignant lymphomas. N Engl J Med 317: 1185-1189.
85. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
86. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
87. Wilson WH, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Dunleavy K et al. (2008). A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol 26: 8511.
88. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB et al. (2007). The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 13: 7191-7198.
89. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. (1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291.
90. Zha H, Reed JC. (1997). Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 272: 31482-31488.
91. Zhang L, Insel PA. (2001). Bcl-2 protects lymphoma cells from apoptosis but not growth arrest promoted by cAMP and dexamethasone. Am J Physiol Cell Physiol 281: C1642-C1647.
92. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. (1997). Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413.
93. Zou H, Li Y, Liu X, Wang X. (1999). An APAF-1. cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274: 11549-11556.